Axsome Therapeutics (AXSM) Cash from Investing Activities (2015 - 2026)
Axsome Therapeutics' (AXSM) quarterly Cash from Investing Activities came in at -$121000.0 in Q1 2026, up 64.2% year-on-year from -$73690.1 in Q1 2025, and down 70.42% quarter-over-quarter from -$71000.0 in Q4 2025.
Axsome Therapeutics (AXSM) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Axsome Therapeutics has disclosed Cash from Investing Activities across 12 years of filings, most recently posting -$121000.0 for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$121000.0, up 64.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$263000.0 (up 48.43% YoY), and the FY2025 annual result was -$480000.0, down 77.78% from the prior year.
- Cash from Investing Activities came in at -$121000.0 for Q1 2026 at Axsome Therapeutics, down from -$71000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$7000.0 in Q4 2023 to a low of -$53.2 million in Q2 2022.
- The 5-year median for Cash from Investing Activities is -$90000.0 (2024), against an average of -$3.2 million.
- Across the five-year window, Cash from Investing Activities tumbled 281941.64% in 2022 and surged 99.75% in 2023, its largest moves.
- Axsome Therapeutics' Cash from Investing Activities stood at -$181000.0 in 2022, then soared by 96.13% to -$7000.0 in 2023, then tumbled by 328.57% to -$30000.0 in 2024, then tumbled by 136.67% to -$71000.0 in 2025, then slumped by 70.42% to -$121000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$121000.0 (Q1 2026), -$71000.0 (Q4 2025), and -$58000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Axsome Therapeutics | 12.84 Bn | 12.54 Bn | 176.48 Mn | -121,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121,000.00 |
| Mar 31, 2026 | -121,000.00 |
| Dec 31, 2025 | -71,000.00 |
| Dec 31, 2025 | -71,000.00 |
| Sep 30, 2025 | -58,000.00 |
| Sep 30, 2025 | -58,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -338,000.00 |
| Mar 31, 2025 | -338,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | -90,000.00 |
| Sep 30, 2024 | -90,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Mar 31, 2024 | -98,000.00 |
| Mar 31, 2024 | -98,000.00 |
| Dec 31, 2023 | -7,000.00 |
| Dec 31, 2023 | -7,000.00 |